Cerity Partners LLC Decreases Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Cerity Partners LLC trimmed its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 8.6% in the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 51,687 shares of the medical equipment provider's stock after selling 4,877 shares during the quarter. Cerity Partners LLC's holdings in Hologic were worth $3,193,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of HOLX. Geode Capital Management LLC boosted its position in Hologic by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider's stock worth $412,159,000 after purchasing an additional 144,838 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Hologic by 3.0% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider's stock valued at $322,272,000 after buying an additional 129,035 shares in the last quarter. Invesco Ltd. lifted its position in shares of Hologic by 16.4% during the 4th quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock valued at $293,434,000 after buying an additional 572,187 shares in the last quarter. Northern Trust Corp lifted its position in shares of Hologic by 26.9% during the 4th quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock valued at $226,898,000 after buying an additional 668,086 shares in the last quarter. Finally, Hsbc Holdings PLC lifted its position in shares of Hologic by 12.5% during the 4th quarter. Hsbc Holdings PLC now owns 2,770,281 shares of the medical equipment provider's stock valued at $199,723,000 after buying an additional 307,109 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Hologic

In other news, Director Martin D. Madaus bought 5,445 shares of the stock in a transaction on Wednesday, May 7th. The stock was acquired at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the acquisition, the director owned 5,445 shares of the company's stock, valued at $300,781.80. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.88% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on HOLX shares. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Stephens lowered their price objective on Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 13th. Wall Street Zen cut Hologic from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Raymond James Financial reaffirmed an "outperform" rating and set a $71.00 price objective (down from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Finally, Citigroup raised Hologic from a "neutral" rating to a "buy" rating and lifted their target price for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $77.33.

Hologic Price Performance

NASDAQ:HOLX traded up $1.35 during trading hours on Tuesday, reaching $65.04. The stock had a trading volume of 222,724 shares, compared to its average volume of 2,377,409. The stock has a market capitalization of $14.49 billion, a PE ratio of 27.46, a PEG ratio of 2.35 and a beta of 0.55. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24. The company has a 50 day moving average price of $62.46 and a two-hundred day moving average price of $63.12. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The company's revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.03 EPS. As a group, sell-side analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.